A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health

*Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA; and

†Department of Pharmacotherapy and Outcomes Science, Hampton VA Medical Center, Hampton VA.

Correspondence: John Bucheit, PharmD, School of Pharmacy, Virginia Commonwealth University, 410 N 12th St, PO Box #980533, Richmond, VA 23298 (e-mail: [email protected]).

The authors report no conflicts of interest.

留言 (0)

沒有登入
gif